New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 9, 2014
09:13 EDTAAL, COH, CELG, KKR, LXRX, GRMN, SDRL, SLXP, MSM, SIMG, AVAV, BOBE, LO, RAI, GIMO, TCS, BPOn The Fly: Pre-market Movers
HIGHER: American Airlines (AAL), up 5.5% after reporting its June traffic rose 1%, forecasting its 2014 total system capacity to be up 3% from last year... AeroVironment (AVAV), up 5.5% after reporting better than expected Q4 earnings results... Reynolds American (RAI), up 1.3% after Daily Mail reported that British American Tobacco (BTI) is rumored to be near a deal to buy out the stake in Reynolds it does not already own, which would prevent a Reynolds takeover of Lorillard (LO). Lorillard shares are down 1.4% in pre-market trade following the report... Lexicon (LXRX), up 11.5% after announcing JDRF, the world's largest non-profit supporter of type 1 diabetes research, will provide funding to support a Phase 2 trial to evaluate the efficacy and safety of LX4211... Seadrill (SDRL), up 3% after cancelling contemplated convertible bond issuance... KKR (KKR), up 1.3% after upgraded to Outperform at Credit Suisse. DOWN AFTER EARNINGS: Container Store (TCS), down 15%... Bob Evans (BOBE), down 1.2%... MSC Industrial (MSM), down 3%. ALSO LOWER: Gigamon (GIMO), down 32% following downgrades at five firms after the company lowered its Q2 revenue guidance... Garmin (GRMN), down 2.7% following downgrade at Pacific Crest... Silicon Image (SIMG), down 11% after cutting second quarter guidance... Salix (SLXP), down 4% after announcing deal to combine with Cosmo Technologies... Celgene (CELG), down 1.5% after OTEZLA did not achieve primary endpoint in Phase III trial... Coach (COH), down 0.7% following downgrade at Buckingham... BP (BP), down 1% after downgraded at Deutsche Bank.
News For AAL;TCS;GIMO;RAI;LO;BOBE;AVAV;SIMG;MSM;SLXP;SDRL;GRMN;LXRX;KKR;CELG;COH;BP From The Last 14 Days
Check below for free stories on AAL;TCS;GIMO;RAI;LO;BOBE;AVAV;SIMG;MSM;SLXP;SDRL;GRMN;LXRX;KKR;CELG;COH;BP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
August 20, 2014
09:25 EDTBOBESadell wins at least five board seats at Bob Evans, CNBC reports
Subscribe for More Information
08:02 EDTCELGBristol-Myers, Celgene enter collaboration agreement for OPDIVO, ABRAXANE
Subscribe for More Information
07:19 EDTSLXPPossible Allergan Salix deal could be 8% accretive in '15-'16, says Wells Fargo
After The Wall Street Journal reported that Allergan (AGN) had approached Salix (SLXP) and other companies about a potential acquisition, Wells Fargo thinks that a largely debt financed purchase of Salix could be 8% accretive for Allergan in 2015-2016, reaching 12% accretion in 2018.
07:04 EDTSLXPSalix buyout price could be near $192 per share, says William Blair
William Blair believes a combined Allergan (AGN) and Salix (SLXP) would be very attractive. The firm estimates a potential takeover price for Salix towards the high end of its $176-$192 per share range. Salix rose 16% yesterday to $160.80 after Wall Street Journal reported that Allergan approached the company and at least one other about a takeover.
07:01 EDTGRMNGarmin introduces first Android-based fleet navigators
Subscribe for More Information
August 19, 2014
17:14 EDTSLXPOn The Fly: Closing Wrap
Subscribe for More Information
16:52 EDTSLXPAllergan all-cash deal would reduce hostile bid chances, says BMO Capital
Subscribe for More Information
14:40 EDTSLXPSterne Agee says Allergan could pay up to $190 for Salix and still be accretive
Subscribe for More Information
13:28 EDTSLXPJazz moves higher after WSJ report of Salix approach by Allergan
Subscribe for More Information
13:15 EDTSLXPSalix options active after WSJ report of Allergan approach
Subscribe for More Information
13:13 EDTSLXPAllergan approached Salix, one other about takeover, WSJ reports
Subscribe for More Information
13:06 EDTSLXPSalix jumps 6% to $147.85 after WSJ report of Allergan approach
Subscribe for More Information
13:05 EDTSLXPAllergan approached Salix about takeover, WSJ reports
10:39 EDTKKRKKR hires Rothschild for sale of Northgate's public sector unit, Reuters says
KKR has engaged Rothschild to arrange for the sale of the public sector division of its software firm Northgate Information Solutions which may fetch around $600M, says Reuters. Reference Link
10:13 EDTLXRXOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: CNOOC (CEO) downgraded to Hold from Buy at Jefferies... Guess (GES) downgraded to Neutral from Overweight at Piper Jaffray... Ingersoll-Rand (IR) downgraded at RW Baird... Lehigh Gas (LGP) downgraded to Neutral from Buy at Ladenburg... Lexicon (LXRX) downgraded to Hold from Buy at Gabelli... Monster Beverage (MNST) downgraded to Neutral from Buy at SunTrust... Nobel Biocare (NBHGY) downgraded to Hold from Buy at Berenberg... Saint Joe Co. (JOE) downgraded to Market Perform from Outperform at Raymond James... SolarCity (SCTY) downgraded at RW Baird.
09:38 EDTCELGActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL GILD TSLA CELG VLO VZ FB HD
08:27 EDTLXRXLexicon downgraded to Hold from Buy at Gabelli
Subscribe for More Information
08:19 EDTAALFAA issues NOTAM restricting U.S. operations from flying over Syria
The Federal Aviation Administration issued a new Notice To Airmen restricting U.S. operators from flying in the Damascus Flight Information Region, which includes all of Syria. The FAA said, "This replaces the current NOTAM in place that strongly advises U.S. operators against flying in that airspace and requires them to contact the FAA before they operate in that airspace. Based on an updated assessment of the risk associated with such operations and the lack of any requests from operators wishing to fly in this airspace, we believe it prudent to prohibit U.S. operators from flying into, out of, and over Syria. The ongoing armed conflict and volatile security environment in Syria poses a serious potential threat to civil aviation. Armed extremist groups in Syria are known to be equipped with a variety of anti-aircraft weapons which have the capability to threaten civilian aircraft. Opposition groups have successfully shot down Syrian military aircraft using these anti-aircraft weapon systems during the course of the conflict. Opposition elements have previously warned civilian air carriers against providing service to Syria. Due to the presence of anti-aircraft weapons among the extremist groups and ongoing fighting in various locations throughout Syria, there is a continuing significant potential threat to civil aviation operating in Syrian airspace." Publicly traded companies in the airline industry include American Airlines (AAL), Delta Air Lines (DAL), JetBlue (JBLU), Southwest (LUV) and United Continental (UAL).
07:33 EDTCELGCelgene announces publication of REVLIMID combination results
Celgene announced that results of a study evaluating the combination of REVLIMID with rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate and prednisone in untreated diffuse large b-cell lymphoma were published online ahead of print in the Journal of Clinical Oncology. In a phase II, open label, single arm study, 64 patients with newly diagnosed, untreated, stage II-IV CD20 positive DLBCL received 25 mg of lenalidomide on days 1-10 with standard dose R-CHOP every 21 days for six cycles. All patients received pegfilgrastim on day two of each cycle and aspirin prophylaxis throughout. The primary endpoint was event-free survival with secondary endpoints of progression free survival and overall survival. A one-stage binomial design was used to assess the efficacy and tolerability of REVLIMID with R-CHOP. Of the 64 patients enrolled, 60 were eligible for response evaluation. In these patients, the overall response rate was 98% with 80% achieving a complete response. The 24-month EFS, which was identical to PFS, and OS rates were 59% and 78%, respectively. The company said, "This study demonstrated that the addition of lenalidomide to conventional R-CHOP resulted in similar PFS rates and OS rates between sub-types. This is intriguing as patients with the non-GCB phenotype have traditionally experienced poorer outcomes. The results of this study support further evaluation of this regimen in this sub-type of DLBCL.
07:02 EDTSLXPSalix announces early termination of HSR Waiting Period for Cosmo transaction
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use